Intsel Chimos aims at reinforcing its offer to patients and healthcare professionals and has thus invested in two entities with strong growth potential. By acquiring Diverchim CDMO (July 2017) and Centre Lab (February 2018), Intsel Chimos Group strengthens its services to French hospitals and enhances its involvement in the pharmaceutical supply chain at the service of the patients.
In July 2017, Intsel Chimos became the majority shareholder of Diverchim CDMO, a French leader in organic synthesis of original molecules, created in 2000 and located in Roissy-en-France, Diverchim CDMO is able to manufacture Active Ingredients in small quantities from a few grams to hundreds of kilograms and is dedicated to Pharmaceutical and Cosmetic Industries.
Diverchim CDMO, thanks to its R&D historical know-how, offers the combined services of a Contract Research Organization (CRO) and a Custom Manufacturing Organization (CMO) and is able to switch from medical chemistry to recurrent productions based on robust and validated processes.
More information on www.diverchim.com
Intsel Chimos took over Terali laboratories in February 2018 and created Centre Lab laboratories, which develops and manufactures specials, medical devices, well-being products and cosmetics in small to medium batches. Centre Lab can also import and certify batches for the release of non-sterile products on the european market.
The manufacturing site which is based in France, in Guéret, is certified as to Good Manufacturing Practices for liquid, semi-solid (pastes) and solid (capsules and tablets) forms.
More information on http://centre-lab.com